COMPARISON OF TOXICITY OF ACUTE OVERDOSES WITH CITALOPRAM AND ESCITALOPRAM

被引:45
作者
Hayes, Bryan D. [1 ]
Klein-Schwartz, Wendy [1 ]
Clark, Richard F. [2 ]
Muller, Allison A. [3 ]
Miloradovich, Jane E. [3 ]
机构
[1] Univ Maryland, Sch Pharm, Maryland Poison Ctr, Baltimore, MD 21230 USA
[2] Univ Calif San Diego, Calif Poison Control Syst San Diego Div, San Diego, CA 92103 USA
[3] Childrens Hosp Philadelphia, Poison Control Ctr, Philadelphia, PA 19104 USA
关键词
citalopram; escitalopram; seizure; toxicity; overdose; ANTIDEPRESSANTS; INGESTIONS; CHIRALITY;
D O I
10.1016/j.jemermed.2008.06.030
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: Seizures and QTc prolongation are associated with citalopram poisoning; however, overdose experience with escitalopram is more limited. Objectives: The goals of this study were to compare citalopram's vs. escitalopram's clinical effects in overdose, including the incidence of seizures. Methods: A retrospective review was conducted for single-substance acute overdoses with citalopram and escitalopram, managed in hospitals, that were reported to six U.S. poison centers from 2002-2005. Results: There were 374 citalopram and 421 escitalopram overdose cases. Gender and ages were similar between the two, with 68-70% females and a median age of 20 years for citalopram and 18 years for escitalopram. Median dose by history was 310 mg for citalopram and 130 mg for escitalopram. More serious outcomes were associated with citalopram overdoses (p < 0.001). Most frequently reported clinical effects with citalopram and escitalopram were tachycardia, drowsiness, hypertension, and vomiting. Seizures (30 vs. 1, respectively, p < 0.001) and tremor (32 vs. 13, respectively, p = 0.001) were more common with citalopram. QTc prolongation occurred in 14 citalopram cases and 7 escitalopram cases (p = 0.109). There was an association between increasing dose and severity of outcome for citalopram (p < 0.001) and escitalopram (p = 0.011). In children < 6 years old, 12 of 66 citalopram and 5 of 57 escitalopram cases experienced toxicity, such as drowsiness, nausea/vomiting, and tachycardia. There were no seizures in this age group. Conclusions: Escitalopram seems to be less toxic than citalopram after an acute overdose; seizures and tremors were more common with citalopram. Initial management of overdoses should include seizure precautions for citalopram and cardiac monitoring for both drugs. (C) 2010 Elsevier Inc.
引用
收藏
页码:44 / 48
页数:5
相关论文
共 50 条
  • [41] Comparison of escitalopram vs. citalopram and venlafaxine in the treatment of major depression in Spain: clinical and economic consequences
    Sicras-Mainar, Antoni
    Navarro-Artieda, Ruth
    Blanca-Tamayo, Milagrosa
    Gimeno-de la Fuente, Victoria
    Salvatella-Pasant, Jordi
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (12) : 2757 - 2764
  • [42] Interaction of citalopram and escitalopram with calf Thymus DNA: A spectrofluorometric, voltammetric, and liquid chromatographic approach
    Dindar, Cigdem Kanbes
    Erkmen, Cem
    Yildirim, Sercan
    Bozal-Palabiyik, Burcin
    Uslu, Bengi
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2021, 195
  • [43] R-citalopram attenuates anxiolytic effects of escitalopram in a rat ultrasonic vocalisation model
    Sánchez, C
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2003, 464 (2-3) : 155 - 158
  • [44] Citalopram Induces Reproductive Toxicity in Male Rats
    Ilgin, Sinem
    Kilic, Gozde
    Baysal, Merve
    Kilic, Volkan
    Korkut, Busra
    Ucarcan, Seyda
    Atli, Ozlem
    BIRTH DEFECTS RESEARCH, 2017, 109 (07): : 475 - 485
  • [45] Neonatal Toxicity Following Maternal Citalopram Treatment
    Eleftheriou, Georgios
    Butera, Raffaella
    Cottini, Federica Cotti
    Bonati, Maurizio
    Farina, Marialuisa
    FETAL AND PEDIATRIC PATHOLOGY, 2013, 32 (05) : 362 - 366
  • [46] Escitalopram causes fewer seizures in human overdose than citalopram
    Yilmaz, Zeynep
    Ceschi, Alessandro
    Rauber-Luethy, Christine
    Sauer, Oliver
    Stedtler, Uwe
    Prasa, Dagmar
    Seidel, Carola
    Hackl, Elisabeth
    Hoffmann-Walbeck, Petra
    Gerber-Zupan, Gabriela
    Bauer, Kathrin
    Kupferschmidt, Hugo
    Kullak-Ublick, Gerd-Achim
    Wilks, Martin
    CLINICAL TOXICOLOGY, 2010, 48 (03) : 207 - 212
  • [47] A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care
    Sorensen, Jan
    Stage, Kurt B.
    Damsbo, Niels
    Le Lay, Agathe
    Hemels, Michiel E. H.
    NORDIC JOURNAL OF PSYCHIATRY, 2007, 61 (02) : 100 - 108
  • [48] A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor: Comparison of cost-effectiveness between escitalopram, citalopram, fluoxetine, and venlafaxine for the treatment of depression in Norway
    C. François
    M. Toumi
    A.-M. Aakhus
    K. Hansen
    The European Journal of Health Economics, 2003, 4 (1) : 12 - 19
  • [49] Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram in patients with major depressive disorder
    Schmitt, Laurent
    Tonnoir, Brigitte
    Arbus, Christophe
    NEUROPSYCHOBIOLOGY, 2006, 54 (04) : 201 - 207
  • [50] Fluorimetric quantitation of citalopram and escitalopram in plasma: developing an express method to monitor compliance in clinical trials
    Serebruany, Victor
    Malinin, Alex
    Dragan, Vadim
    Atar, Dan
    van Zyl, Louis
    Dragan, Anatoly
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2007, 45 (04) : 513 - 520